Related Articles

• Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN^®) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
• Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2‑positive breast cancer in Japan
• Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta‑analysis
• Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience
• Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer)